Indivior: too risky to hold

Can Indivior (INDV) recover from a major setback in its ongoing patent dispute? A US court concluded that an unbranded version of the group’s opioid addiction treatment – made by Indian pharma company Dr Reddy’s – does not breach Individor's patent, clearing the way for lower-priced competition. The highs of recent months – when many courts ruled in favour of Indivior’s various legal proceedings – have been replaced with a crashing comedown. Individor intends to appeal the US District Court for the District of Delaware's decision. The shares plummeted 31 per cent on the day of the announcement and have only made up a small amount of ground since.